More on NAMS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.58 |
|
|||
| Open | $21.39 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $21.39 | ||||
| Day Low | $19.13 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,311,262 | ||||
- U.S. biotech SMids: Q3 earnings preview
- NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $42 at RBC Capital
- Form 4 NewAmsterdam Pharma Co For: Sep 30 Filed by: Kastelein Johannes Jacob Pieter
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma begins Phase 2b trial of obicetrapib in Alzheimer's
- NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
- Stifel on NewAmsterdam Pharma Co NV (NAMS): 'the risk/reward is very compelling'
- EU approves NewAmsterdam and Menarini's obicetrapib drugs
- NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- NewAmsterdam Pharma CEO buys 10,000 shares at $22.65
Entities mentioned with NAMS
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- SPAC | View Related Stories »
- Jefferies & Co | View Related Stories »
- Earnings | View Related Stories »
- F1 | View Related Stories »
- Show More...
